Zeltia Group

Zeltia: Report at 31 December 2005

Madrid (ots/PRNewswire) - Group: - Capital increase at Zeltia. The placement of 10.75 million new shares among qualified international investors raised 65 million euro - R&D expenditure up 24% - Net revenues in 2005: 72 million euro - Net cash position at 31 December 2005: 93 million euro net of short-term financial debt and 51 million euro net of total financial debt PharmaMar: - Yondelis(R): - Phase III pivotal trial on ovarian cancer commenced - Recruitment for the pivotal randomised trial on soft-tissue sarcoma was completed - Aplidin(R): - Phase II studies on prostate and bladder cancer commenced - Combination studies with other chemotherapy agents commenced - Zalypsis(R), PharmaMar's fifth compound to reach clinical trials - PM02734 is PharmaMar's sixth compound to reach clinical trials Xylazel: - Launched a full range of Xylazel-brand wood protecting paints and varnishes. - Conclusion of licensing and marketing agreement with ICI. Isabel Lozano Chief Executive Officer PHARMAMAR, S.A. C/ Reyes, 1. Colmenar Viejo Madrid Telephone +34-91-846-60-00 Catherine Moukheibir Head of Capital Market Strategy ZELTIA, S.A. José Abascal, 2. Madrid Telephone +34-91-444-45-00 Ma Luisa de Francia Chief Financial Officer ZELTIA, S.A. José Abascal, 2. Madrid Telephone +34-91-444-45-00 For a copy of the full results, please refer to www.zeltia.com ots Originaltext: Zeltia Group Im Internet recherchierbar: http://www.presseportal.ch Contact: Isabel Lozano, Chief Executive Officer, PHARMAMAR, S.A., C/ Reyes, 1., Colmenar Viejo, Madrid, Telephone +34-91-846-60-00; Catherine Moukheibir, Head of Capital Market Strategy, ZELTIA, S.A., José Abascal, 2. Madrid, Telephone +34-91-444-45-00; Ma Luisa de Francia, Chief Financial Officer, ZELTIA, S.A., José Abascal, 2. Madrid, Telephone +34-91-444-45-00

Das könnte Sie auch interessieren: